Small Pharma Inc. (DMTTF) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は London, イギリス. 現CEOは George Tziras.
DMTTF を有する IPO日 2021-06-07, に上場 Other OTC, 時価総額 $37.51M.
Small Pharma Inc., a biotechnology company, focuses on developing short-acting psychedelics with therapy for the treatment of mental health conditions. Its clinical program is N,N-dimethyltryptamine assisted therapy to treat major depressive disorder. The company's product includes SPL026 Placebo, which is in clinical Phase IIA for the treatment of major depressive disorder. Its preclinical stage programs include SPL028, a prolonged DMT series; SPL029, an oral DMT series; and SPL801 oral formulation of 6-hydroxynorketamin. The company was incorporated in 2015 and is headquartered in London, the United Kingdom.
